Nanjing’s Lishui District has developed into a vital cluster for China’s new medicine and life health sector, integrating R&D, manufacturing, and commercialization of innovative drugs, high-end medical devices, and biotechnologies. The district hosts leading pharmaceutical enterprises, precision medical institutes, and CRO/CDMO platforms, forming a complete ecosystem from raw material synthesis to finished drugs and digital healthcare solutions. Key focuses include innovative biologics, intelligent medical equipment, and AI-driven diagnostics, supported by collaborations with Nanjing University Medical School and provincial hospitals. Lishui’s specialized industrial parks offer GMP-certified production facilities and pilot testing bases, accelerating the translation of research into market-ready products.